TreatmentsJul 20, 2023
Community statement: BIOCAD
Biocad, a Russian biotechnology company, shares a community statement on its gene therapy product, ANB-004, which is being developed to treat SMA.
SMA Newsroom
TreatmentsJul 17, 2023
Community update from Biogen
We are pleased to share with you the latest community update issued by Biogen.
TreatmentsMay 4, 2023
New interim data on long-term efficacy and safety data up to 7.5 years post-dosing of Zolgensma.
Novartis announced new long-term data for Zolgensma® (onasemnogene abeparvovec).
The latest data from two Long-Term Follow-Up (LTFU) studies, LT-001 and LT-002, show the continued efficacy and durability of Zolgensma across a range of patient populations, with an overall benefit-risk profile that remains favourable, with treated children maintaining motor milestones up to 7.5 years post-dosing.
TreatmentsMar 22, 2023
New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
